Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Payables (2018 - 2025)

Historic Payables for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $1.6 million.

  • Whitehawk Therapeutics' Payables rose 1885.01% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 1885.01%. This contributed to the annual value of $2.2 million for FY2024, which is 6339.44% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Payables stood at $1.6 million, which was up 1885.01% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Payables peaked at $6.5 million during Q1 2023, and registered a low of $1.4 million during Q3 2024.
  • In the last 5 years, Whitehawk Therapeutics' Payables had a median value of $3.3 million in 2025 and averaged $3.5 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 11533.43% in 2021, then crashed by 6339.44% in 2024.
  • Whitehawk Therapeutics' Payables (Quarter) stood at $6.4 million in 2021, then tumbled by 45.35% to $3.5 million in 2022, then soared by 67.6% to $5.9 million in 2023, then crashed by 63.39% to $2.2 million in 2024, then decreased by 24.36% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $3.3 million for Q2 2025, and $3.7 million during Q1 2025.